Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04340557 · ClinicalTrials.gov registry record · Phase 4
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
A Phase 4 study, sponsored by Sharp HealthCare.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT04340557: Completed Phase 4 study, sponsored by Sharp HealthCare.
NCT04340557 is a Phase 4 study that has completed, run by Sharp HealthCare. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04340557, a Phase 4 study, has completed, sponsored by Sharp HealthCare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical ventilation in subjects with mild to moderate hypoxia due to the corona virus that causes COVID-19. Based on previous animal studies, the researchers hypothesize that the addition of an ARB is beneficial in abating acute lung injury in subjects in early stages of SARS-CoV-2 viral induced hypoxia.
Interventions
- DRUG Losartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-03-27 |
| Est. Completion | 2020-06-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04340557
The ClinicalTrials.gov registry entry for NCT04340557 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sharp HealthCare, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Losartan is the first listed.
NCT04340557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04340557 about?
NCT04340557 is a clinical study titled "Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection". The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical ventilation in subjects with mild to moderate hypoxia due to the corona vir...
What is the current status of trial NCT04340557?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2020-03-27. Estimated completion is 2020-06-13.
What interventions are being tested in trial NCT04340557?
The interventions under investigation include: Losartan (DRUG).
Who is sponsoring clinical trial NCT04340557?
This trial is sponsored by Sharp HealthCare, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.